SOFINNOVA-PARTNERS
13.12.2023 07:01:34 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita, an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.
Biovelocita’s newly formed team will provide a hands-on, robust framework for startups, combining direct management, financial backing, and access to Sofinnova’s extensive infrastructure and network. The strategy builds upon Sofinnova’s established track record of nurturing innovative ventures within the healthcare and sustainability sectors. It draws inspiration from the achievements of Italy’s first biotech accelerator, BiovelocITA, co-founded by Gabriella Camboni, Silvano Spinelli and Sofinnova Partners in 2015, which has significantly contributed to the growth of the Italian biotech ecosystem.
Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “With Sofinnova Biovelocita, we are doubling down on our commitment to innovation and company creation in the life sciences. To improve and expand our company-creation toolbox, we have brought together a group of experienced investors and entrepreneurs who have been collaborating with Sofinnova for over a decade, some nearly two decades. With this top-tier team, we look forward to strengthening one of Sofinnova’s strategic pillars: acceleration, which is already making rapid strides in the medical device space with Sofinnova MD Start, our in-house medtech accelerator.”
Key partners of this initiative include:
- Gabriella Camboni, Partner, pivotal in the conception of this strategy as a co-founder and CEO of BiovelocITA. She also co-founded two Sofinnova companies, EOS (Ethical Oncology Science), serving as its COO until its acquisition by Clovis Oncology in 2013, and Novuspharma, which was acquired by Cell Therapeutics, Inc. in 2003.
- Matthieu Coutet, Partner, brings nearly two decades of experience in venture capital and operations, including significant contributions to the launch of biotech startups such as TherAchon and Annapurna Therapeutics, and the founding of AdBio Partners.
- Alex Leech, Partner, an experienced biopharma company builder and a serial CEO, most recently serving as the founding CEO of Alchemab Therapeutics, which raised an $82m Series A investment round.
- Zhizhong (Joel) Yao, Partner, a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellow, instrumental in the launch of several biotech start-ups. Holds a Harvard PhD in Chemical Biology and Systems Biology and did post-doctoral research at the French National Institute of Agricultural Research.
Seghezzi concluded: “We know from our extensive experience that close cooperation between top management teams, world-class scientists, and dedicated financing, forges the path for biotech champions of tomorrow. With this new strategy, we are poised to catalyze transformative innovation in biotechnology.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231212907842/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Robotics and PSYONIC Use Human-Generated Data to Advance Robotic Dexterity16.6.2026 06:01:00 CEST | Press release
ABB Robotics and PSYONIC collaborate to revolutionize grasping and dexterity, a core capability for Autonomous Versatile Robotics™ ABB GoFa™ helps test PSYONIC’s Ability Hand for robotics, combining touch sensing, compliant design and human-derived training data Dexterity remains a major challenge for industry; improved handling can reduce engineering time by up to 30%¹ ABB Robotics is collaborating with California bionics company, PSYONIC, to advance robotic gripping and dexterity using a new approach that utilizes real-world manipulation data from human prosthetic use. By combining the PSYONIC Ability Hand with an ABB GoFa™ cobot, the collaboration will explore how touch and motion data generated by human prosthetic use can be used to train robots to perform delicate, variable tasks that have traditionally been difficult to automate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612749544/en/ “Human dexterity and the i
Signaloid Announces Availability of Amazon AWS Machine Image (AMI) for Accelerating Compute Workloads Ranging from Finance to Reinforcement Learning16.6.2026 06:00:00 CEST | Press release
British computing technology company Signaloid today announced the release of the Signaloid Compute Engine Amazon Machine Image (AMI) via AWS Marketplace. The release enables organizations to deploy Signaloid’s distribution-extended compute hardware (UxHw®) technology within their Amazon Virtual Private Clouds (VPCs). The AMI provides access to UxHw, which delivers orders-of-magnitude performance improvements on x86_64 and ARM (AArch64) AWS Elastic Compute Cloud (EC2) instances. Without requiring software rewrites, UxHw enables existing applications to compute directly on probability distributions, automating algorithms such as Monte Carlo methods in finance and physics, importance sampling in reinforcement learning, and particle filters in physical AI and robotics. The technology works through binary translation and optimization at the LLVM intermediate representation (LLVM IR) level, with optional hardware acceleration via FPGAs and Signaloid’s C0-ASIC that was recently taped-out in
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible CapitalSolutions16.6.2026 01:01:00 CEST | Press release
Founded by former Blackstone executive Vlado Spasov, Trimontium is an institutionally backed alternative asset manager purpose-built to deliver flexible capital solutions across Europe and North America Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to ava
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom